Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03405870 · ClinicalTrials.gov registry record · Phase 1
LIPIDS-P Trial Phase I/II Trial
A Phase 1 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
NCT03405870 is a Phase 1 study that has completed, run by University of Florida. The registered enrollment target is 59 participants.
The verdict
NCT03405870, a Phase 1 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
Study Summary
Briefly, this pilot clinical trial will evaluate preliminary safety and efficacy of the study drug (Smoflipid) at elevating cholesterol levels (primary outcome) in patients with sepsis and moderate organ dysfunction and will also evaluate measures of organ dysfunction, mortality, and biological activity (secondary outcomes).
Interventions
- DRUG Smoflipid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2018-08-17 |
| Est. Completion | 2023-04-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03405870
The ClinicalTrials.gov registry entry for NCT03405870 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Smoflipid is the first listed.
NCT03405870 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03405870 about?
NCT03405870 is a clinical study titled "LIPIDS-P Trial Phase I/II Trial". Briefly, this pilot clinical trial will evaluate preliminary safety and efficacy of the study drug (Smoflipid) at elevating cholesterol levels (primary outcome) in patients with sepsis and moderate organ dysfunction and will also evaluate measures of organ dysfunction, mortality, and biological acti...
What is the current status of trial NCT03405870?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2018-08-17. Estimated completion is 2023-04-26.
What interventions are being tested in trial NCT03405870?
The interventions under investigation include: Smoflipid (DRUG).
Who is sponsoring clinical trial NCT03405870?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.